IRWD
Ironwood Pharmaceuticals, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
24.03
PEG
0.01
P/B
-2.19
P/S
1.94
EV/EBITDA
7.83
DCF Value
$7.10
FCF Yield
22.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
90.6%
Operating Margin
33.2%
Net Margin
8.1%
ROE
-8.2%
ROA
6.1%
ROIC
9.4%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $47.7M | $-2.3M | $-0.01 |
| FY 2025 | $296.2M | $24.0M | $0.15 |
| Q3 2025 | $122.1M | $40.1M | $0.23 |
| Q2 2025 | $85.2M | $23.6M | $0.14 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.17
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.